

# Jamie L Wagner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5270620/publications.pdf>

Version: 2024-02-01

36  
papers

419  
citations

1039406

9  
h-index

794141

19  
g-index

37  
all docs

37  
docs citations

37  
times ranked

604  
citing authors

#	ARTICLE	IF	CITATIONS
1	Best Practices in Syllabus Design. American Journal of Pharmaceutical Education, 2023, 87, ajpe8995.	0.7	5
2	Diabetic foot infections: A microbiologic review. Foot, 2022, 51, 101877.	0.4	13
3	Overcoming Past Perceptions and a Profession-Wide Identity Crisis to Reflect Pharmacy's Future. American Journal of Pharmaceutical Education, 2022, 86, 8829.	0.7	7
4	Intravenous versus Oral Step-Down for the Treatment of Staphylococcus aureus Bacteremia in a Pediatric Population. Pharmacy (Basel, Switzerland), 2022, 10, 16.	0.6	3
5	Real-world, multicentre evaluation of the incidence and risk factors for non-susceptible Stenotrophomonas maltophilia isolates. Journal of Global Antimicrobial Resistance, 2022, 28, 282-287.	0.9	11
6	Which pharmacists are performing antimicrobial stewardship: A national survey and a call for collaborative efforts. Antimicrobial Stewardship & Healthcare Epidemiology, 2022, 2, .	0.2	6
7	Feeding the Soul via Creation of a Suborganization to Promote a Sense of Community. American Journal of Pharmaceutical Education, 2022, , 8927.	0.7	1
8	A Continuing Education Activity Durably Addressed Knowledge Gaps Related to Penicillin Allergies Among Pharmacists and Pharmacy Technicians. Journal of Pharmacy Technology, 2022, 38, 18-25.	0.5	0
9	Effect of Obesity on Clinical Outcomes of Patients Treated With Cefepime. Journal of Pharmacy Technology, 2021, 37, 30-35.	0.5	2
10	An evaluation of antipseudomonal dosing on the incidence of treatment failure. SAGE Open Medicine, 2021, 9, 205031212110009.	0.7	0
11	Frequency of and risk factors for carbapenem-resistant Enterobacteriaceae. Journal of Medical Microbiology, 2021, 70, .	0.7	3
12	Effect of Obesity on Clinical Failure of Patients Treated With $\beta$ -Lactams. Open Forum Infectious Diseases, 2021, 8, ofab212.	0.4	7
13	Optimizing rapid diagnostics and diagnostic stewardship in Gram-negative bacteremia. Pharmacotherapy, 2021, 41, 676-685.	1.2	4
14	Risk factors for development of initial Clostridioides difficile infection. Journal of Global Antimicrobial Resistance, 2021, 25, 18-22.	0.9	1
15	Impact of Communication Method and Timeliness on Student and Faculty Perception of Professionalism and Value. American Journal of Pharmaceutical Education, 2021, , 8391.	0.7	0
16	Influence of Probiotics on the Development of Clostridioides difficile Infection in Patients Receiving Fluoroquinolones. Pharmacy (Basel, Switzerland), 2021, 9, 141.	0.6	3
17	Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant Enterococci. Pharmacy (Basel, Switzerland), 2021, 9, 175.	0.6	6
18	Impact of Obesity on Ceftriaxone Efficacy. Diseases (Basel, Switzerland), 2020, 8, 27.	1.0	6

#	ARTICLE	IF	CITATIONS
19	Fluoroquinolone Versus Nonfluoroquinolone Treatment of Bloodstream Infections Caused by Chromosomally Mediated AmpC-Producing Enterobacteriaceae. <i>Antibiotics</i> , 2020, 9, 331.	1.5	1
20	Allergic Reactions and Cross-Reactivity Potential with Beta-Lactamase Inhibitors. <i>Pharmacy (Basel, Switzerland)</i> , 2019, 7, 103.	0.6	10
21	Cephalosporins: A Focus on Side Chains and $\beta$ -Lactam Cross-Reactivity. <i>Pharmacy (Basel, Switzerland)</i> , 2019, 7, 103.	0.6	67
22	Trends in and Predictors of Carbapenem Consumption across North American Hospitals: Results from a Multicenter Survey by the MAD-ID Research Network. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	10
23	Impact of Obesity on Acyclovir-Induced Nephrotoxicity. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz121.	0.4	10
24	Growing resistance in <i>Stenotrophomonas maltophilia</i> ?. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 2004-2005.	0.5	7
25	Impact of an antifungal stewardship intervention on optimization of candidemia management. <i>Therapeutic Advances in Infectious Disease</i> , 2018, 5, 3-10.	1.1	12
26	Omadacycline Enters the Ring: A New Antimicrobial Contender. <i>Pharmacotherapy</i> , 2018, 38, 1194-1204.	1.2	20
27	Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic. <i>Pharmacotherapy</i> , 2018, 38, 935-946.	1.2	76
28	Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C. <i>International Journal of Hepatology</i> , 2016, 2016, 1-8.	0.4	29
29	Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum $\beta$ -lactamase urinary tract infections. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 56-60.	1.1	43
30	Surgical prophylaxis with gram-negative activity for reduction of surgical site infections after microvascular reconstruction for head and neck cancer. <i>Head and Neck</i> , 2016, 38, 1449-1454.	0.9	14
31	Days of Therapy and Antimicrobial Days: Similarities and Differences Between Consumption Metrics. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 971-973.	1.0	3
32	Intravenous Vancomycin Dosing in the Elderly: A Focus on Clinical Issues and Practical Application. <i>Drugs and Aging</i> , 2016, 33, 845-854.	1.3	20
33	Acute hepatic injury with amphotericin B deoxycholate in an immunocompetent patient. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2016, 7, 112.	0.2	2
34	Secular Trends Associated with Enterobacteriaceae with a Cefepime Susceptible-Dose-Dependent MIC. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1822-1823.	1.4	2
35	Epidemiology and Outcomes Associated With Anemia During Long-Term Support With Continuous-Flow Left Ventricular Assist Devices. <i>Journal of Cardiac Failure</i> , 2014, 20, 387-391.	0.7	17
36	A Primer on Post-COVID-19 Conditions and Implications for Clinical Pharmacists. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 0, , .	0.5	0